Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Badimon JJ et al. (1990) Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85: 1234–1241

    Article  CAS  Google Scholar 

  2. Hovingh GK et al. (2004) A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol 44: 1429–1435

    Article  CAS  Google Scholar 

  3. Barter PJ et al. for the ILLUMINATE Investigators (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109–2122

    Article  CAS  Google Scholar 

  4. van der Steeg WA et al. (2008) High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 51: 634–642

    Article  CAS  Google Scholar 

  5. Forrest MJ et al. (2007) Torcetrapib-induced blood pressure elevation is independent of cholesteryl ester transfer protein inhibition and is accompanied by an increase in circulating aldosterone levels [abstract #4020]. In Late-breaking basic science abstracts: from the American Heart Association Scientific Sessions 2007 Orlando, Florida November 4–7, 2007. Circ Res 101: 1204–1211

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John JP Kastelein.

Ethics declarations

Competing interests

JJP Kastelein has received Speakers' Bureau honoraria and research support from Merck, Pfizer, and Roche. In addition, he has acted as Consultant for Merck, Pfizer, Roche, and Novartis. M Vergeer declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vergeer, M., Kastelein, J. Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia. Nat Rev Cardiol 5, 302–303 (2008). https://doi.org/10.1038/ncpcardio1190

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio1190

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing